Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5331586 | 0.78 | TDP1 (0.39) | TDP1 | |
| SCHEMBL13565274 | 0.78 | NPY5R (0.37) | NPY5R | |
| SCHEMBL17090029 | 0.78 | NPY5R (0.37) | NPY5R | |
| SCHEMBL4064940 | 0.76 | CA12 (0.37) | — | |
| SCHEMBL4064934 | 0.76 | CA12 (0.37) | — | |
| SCHEMBL4751765 | 0.75 | KMT2A (0.48) | — | |
| SCHEMBL4751768 | 0.75 | KMT2A (0.48) | — | |
| SCHEMBL1960773 | 0.75 | — | — | |
| SCHEMBL13450369 | 0.75 | CA12 (0.50) | — | |
| SCHEMBL5130918 | 0.75 | TDP1 (0.44) | TDP1NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009035855-A2 | NOVEL USES OF HALOGENATED ALKYL SULFONAMIDES | H. LUNDBECK A/S (DK) | 2009-03-19 | — | — | WO | disclosed |
| WO-2007103295-A2 | HALOGENATED SULFONAMIDE DERIVATIVES | H. LUNDBECK A/S (DK) | 2007-09-13 | — | — | WO | disclosed |
| US-20070213376-A1 | Halogenated sulfonamide derivatives | H. LUNDBECK A/S (DK) | 2007-09-13 | — | — | US | disclosed |
| WO-2007002126-A1 | ALKYL SULFONAMIDE DERIVATIVES | H. LUNDBECK A/S (DK) | 2007-01-04 | — | — | WO | disclosed |
| US-20060293341-A1 | Alkyl sulfonamide derivatives | H. LUNDBECK A/S (DK) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213376-A1 | Halogenated sulfonamide derivatives | NPY5R, NPY2R, SSTR5 | TDP1 3232/4885NPY5R 1/4885 |
| US-20060293341-A1 | Alkyl sulfonamide derivatives | NPY5R, NPY1R, NPY4R | TDP1 2989/4885NPY5R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.